Evidence map›Paper›PMID 35267137›Full record

ArticleMetabolic brain disease2022

Novel mutation of SIK1 gene causing a mild form of pediatric epilepsy in a Chinese patient.

Wangshu Xu, Wenqun Zhang, Lili Cui, Lei Shi, Bin Zhu, Tina-Jie Lyu, Wenping Ma

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Metabolic brain disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Wangshu Xu *Neuroinfection and Neuroimmunology Center, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, China.
Wenqun Zhang *Department of Pediatrics, Chongqing Youyoubaobei Women and Children's Hospital, Chongqing, 400000, China.
Lili Cui *Department of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, 100053, China.
Lei ShiDepartment of Laboratory, PLA Rocket Force Characteristic Medical Center, Beijing, 100088, China.
Bin ZhuDepartment of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, No. 119 South Fourth Ring Road West, Fengtai District, Beijing, 100070, China. zbtcm@163.com.
Tina-Jie LyuChina National Clinical Research Center for Neurological Diseases, No. 119 South Fourth Ring Road West, Fengtai District, Beijing, 100070, China. lvtianjie@bjmu.edu.cn.
Wenping MaDepartment of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, No. 119 South Fourth Ring Road West, Fengtai District, Beijing, 100070, China. mawenping@bjmu.edu.cn.ORCID http://orcid.org/0000-0002-1564-4584
Capital Medical University · CNChildren's Hospital of Chongqing Medical University · CNNational Clinical Research Center for Digestive Diseases · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Developmental and Epileptic Encephalopathy (DEE) is a group of disorders affecting children at early stages of infancy, which is characterized by frequent seizures, epileptiform activity on EEG, and developmental delayor regression. Developmental and epileptic encephalopathy-30 (DEE30) is a severe neurologic disorder characterized by onset of refractory seizures soon after birth or in the first months of life. Which was recently found to be caused by heterozygous mutations in the salt-inducible kinase SIK1. In this study, we investigated a patient with early onset epilepsy. DNA sequencing of the whole coding region revealed a de novel heterozygous nucleotide substitution (c.880G > A) causing a missense mutation (p.A294T). This mutation was classified as variant of unknown significance (VUS) by American College of Medical Genetics and Genomics (ACMG). To further investigate the pathogenicity and pathogenesis of this mutation, we established a human neuroblastoma cell line (SH-SY5Y) stably-expressing wild type SIK1 and A294T mutant, and compared the transcriptome and metabolomics profiles. We presented a pediatric patient suffering from infantile onset epilepsy. Early EEG showed a boundary dysfunction of activity and MRI scan of the brain was normal. The patient responded well to single anti-epileptic drug treatment. Whole-exome sequencing found a missense mutation of SIK1 gene (c.880G > A chr21: 43,420,326 p. A294T). Dysregulated transcriptome and metabolome in cell models expressing WT and MUT SIK1 confirmed the pathogenicity of the mutation. Specifically, we found MEF2C target genes, certain epilepsy causing genes and metabolites are dysregulated by SIK1 mutation. We found MEF2C target genes, certain epilepsy causing genes and metabolites are dysregulated by SIK1 mutation. Our finding further expanded the disease spectrum and provided novel mechanistic insights of DEE30.

Indexed as

EpilepsyAsian PeopleChildChinaHumansMutationProtein Serine-Threonine KinasesSeizuresProtein Serine-Threonine KinasesSIK1 protein, humanDevelopmental and epileptic encephalopathy-30Early infantile epileptic encephalopathyGenetic epilepsyMetabolomeTranscriptome

Identifiers

PMID35267137
OpenAlexW4220717664

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.